QA: Mylan II B.V. in us_pharma/2018

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001623613_2019_Mylan_II_B_V.pdf

Logs

warning Missing logo subcommand.report {}
info Minor missing amount for aggregate added to remainder industry.us_generic {'aggregate': 'Liabilities', 'missing_ratio': 0.014064387475313021, 'aggregate_val': 20567800000, 'exp_sum': 20861200000, 'exp_to_value': {'LiabilitiesCurrent': 4587800000, 'LiabilitiesNoncurrent': 14258000000, 'remainder_Liabilities': 2015400000}}
info Failed to set obs_EconomicCapitalRatio industry.us_generic {'reason': "KeyError('0001623613')"}
info Added remainder_ComprehensiveNetIncome directly from 10K industry.us_generic {}

Graph

Absolute values for 0001623613, Mylan II B.V.

  xvar xval
0 AssetsCurrent 6,367,700,000
1 IntangibleAssetsNetIncludingGoodwill 23,412,400,000
2 PropertyPlantAndEquipmentNet 2,170,200,000
3 remainder_Assets 784,600,000
4 LiabilitiesCurrent 4,587,800,000
5 LiabilitiesNoncurrent 14,258,000,000
6 remainder_Liabilities 1,722,000,000
7 CostOfGoodsAndServicesSold 7,432,300,000
8 SellingGeneralAndAdministrativeExpense 2,441,000,000
9 ResearchAndDevelopmentExpense 704,500,000
10 remainder_Expenses 438,700,000
11 remainder_Revenues 11,433,900,000
12 remainder_NetIncome -64,900,000
13 remainder_ComprehensiveNetIncome -1,072,600,000
  yvar yval
0 Assets 32,734,900,000
1 Liabilities 20,567,800,000
2 Expenses 11,016,500,000
3 Revenues 11,433,900,000
4 StockholdersEquity 12,167,100,000
5 NetIncome 352,500,000
6 ComprehensiveNetIncome -183,800,000
7 BaseVar 38,445,300,000
8 EconomicCapitalRatio 0.778

Edgar->Model Mapping

Feature Distribution

Change over Time